Advertisement

Topics

Kiadis raises €23.4m to develop immunotherapy for GVHD

03:26 EDT 14 Mar 2018 | Pharmaceutical Business Review

Kiadis Pharma has raised €23.4m of funding in a private placement of 2.6 million new shares, for developing a T-cell immunotherapy product to reduce Graft versus Host Disease (GVHD) in hematopoietic stem cell transplantations (HSCT).

Original Article: Kiadis raises €23.4m to develop immunotherapy for GVHD

NEXT ARTICLE

More From BioPortfolio on "Kiadis raises €23.4m to develop immunotherapy for GVHD"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Immunology
Allergies Automimmune Disease Human Papillomavirus (HPV) Immunology Vaccine Immunology is the study of immunity and the defence mechanisms of the body. A greater understanding of immunology is needed to develop vaccines, understand ...

Stem Cells
Track and monitor developments in stem cell research and commercial development.  Follow the tabs above to read the latest global news, research, clinical trials on stem cells and follow companies active in the stem cell industry.  BioPort...